Although gliosis is a normal response to brain injury, reports on the extent of astrogliosis in the degenerating substantia nigra in Parkinson's disease (PD) are conflicting. It has also been recently suggested that accumulation of nigral α-synuclein in this disorder might suppress astrocyte activation which in turn could exacerbate the degenerative process. This study examined brain protein levels (intact protein, fragments, and aggregates, if any) of astroglial markers and their relationship to α-synuclein in PD and in the positive control parkinson-plus conditions multiple system atrophy (MSA) and progressive supranuclear palsy (PSP). Autopsied brain homogenates of patients with PD (n = 10), MSA (n = 11), PSP (n = 11) and matched controls (n = 10) were examined for the astroglial markers glial fibrillary acidic protein (GFAP), vimentin, and heat shock protein-27 (Hsp27) by quantitative immunoblotting. As expected, both MSA (putamen N substantia nigra N caudate N frontal cortex) and PSP (substantia nigra N caudate N putamen, frontal cortex) showed widespread but regionally specific pattern of increased immunoreactivity of the markers, in particular for the partially proteolyzed fragments (all three) and aggregates (GFAP). In contrast, immunoreactivity of the three markers was largely normal in PD in brain regions examined with the exception of trends for variably increased levels of cleaved vimentin in substantia nigra and frontal cortex. In patients with PD, GFAP levels in the substantia nigra correlated inversely with α-synuclein accumulation whereas the opposite was true for MSA. Our biochemical findings of generally
Introduction
The pathological hallmarks of idiopathic Parkinson's disease (PD) are loss of dopaminergic neurones originating in the substantia nigra (SN) (Hassler, 1938; Greenfield and Bosanquet, 1953; Ehringer and Hornykiewicz, 1960 ) and accumulation of α-synuclein-immunoreactive aggregates in neuronal (Spillantini et al., 1997; Wakabayashi et al., 1997) and glial cells (Wakabayashi et al., 2000; Hishikawa et al., 2001; Braak et al., 2007 ) (see (Jellinger, 2012) for an extensive review).
As the cause of this "α-synucleinopathy" is unknown, there is a need to identify useful therapeutic targets in PD. Gliosis, a normal response to brain injury, has historically been described as a core feature in PD (Hassler, 1953; Forno, 1966 Forno, , 1990 Earle, 1968; Bernheimer et al., Neurobiology of Disease 82 (2015) [243] [244] [245] [246] [247] [248] [249] [250] [251] [252] [253] Abbreviations: GCI, glial cytoplasmic inclusion; GFAP, glial fibrillary acidic protein; HMW, high molecular weight; Hsp27, heat shock protein-27; LB, Lewy body; LMW, low molecular weight; MSA, multiple system atrophy; NFT, neurofibrillary tangle; NSE, neuron-specific enolase; PD, Parkinson's disease; PSP, progressive supranuclear palsy; SN, substantia nigra pars compacta; tHsp27, truncated heat shock protein-27.
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